Bucladin
Bucladin Uses, Dosage, Side Effects, Food Interaction and all others data.
Bucladin is an antihistamine medication with both antiemetic and anticholinergic effects , belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated. In addition to the above conditions, buclizine has been studied in the treatment of migraine attacks and in the treatment of nausea and vomiting during pregnancy.
Bucladin is a piperazine-derivative antihistamine used as an antivertigo/antiemetic agent. Bucladin is used in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. Additionally, it has been used in the management of vertigo in diseases affecting the vestibular apparatus. Although the mechanism by which buclizine exerts its antiemetic and antivertigo effects has not been fully elucidated, its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone. It also possesses anticholinergic, antihistaminic, central nervous system depressant, and local anesthetic effects.
Trade Name | Bucladin |
Generic | Buclizine |
Buclizine Other Names | Buclizina, Buclizine, Buclizinum |
Type | |
Formula | C28H33ClN2 |
Weight | Average: 433.028 Monoisotopic: 432.233226773 |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Bucladin is an antihistamine and antiemetic drug for the treatment of allergy symptoms and prevention of nausea and vomiting.
For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).
Bucladin is also used to associated treatment for these conditions: Allergies, Nausea
How Bucladin works
Vomiting (emesis) is essentially a protective mechanism for removing irritant or otherwise harmful substances from the upper GI tract. Emesis or vomiting is controlled by the vomiting centre in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ). The vomiting centre possesses neurons which are rich in muscarinic cholinergic and histamine containing synapses. These types of neurons are especially involved in transmission from the vestibular apparatus to the vomiting centre. Motion sickness principally involves overstimulation of these pathways due to various sensory stimuli. Hence the action of buclizine which acts to block the histamine receptors in the vomiting centre and thus reduce activity along these pathways. Furthermore since buclizine possesses anti-cholinergic properties as well, the muscarinic receptors are similarly blocked.
Elimination Route
Rapidly absorbed following oral administration.
Innovators Monograph
You find simplified version here Bucladin